Browse / CJC-1295

CJC-1295

GHRH analogue (DAC and non-DAC forms)

Injectable CJC/IPA blends: follow the vial; research-community ranges are often 100 mcg-class per peptide per injection 1–2× daily for non-DAC; weekly-scale for DAC literature PHARMACOLOGY

Overview

What is CJC-1295?

CJC-1295 is a tetrasubstituted GHRH analogue. Drug-affinity complex (DAC) versions extend half-life via albumin binding; non-DAC (“Mod GRF 1-29”) versions are shorter-acting. Catalog SKUs may list either. All catalog material is for laboratory research use only.

Key Benefits

GHRH-receptor GH/IGF-1 axis research, DAC vs non-DAC kinetic options, frequent pairing with ipamorelin in pulsatile protocols.

Mechanism of Action

GHRH-receptor activation on somatotrophs increases GH transcription and release. DAC chemistry changes duration, not the core receptor.

Quick Start Guide

Typical Dose CJC/IPA blends: follow the vial; research-community ranges are often 100 mcg-class per peptide per injection
How Often 1–2× daily for non-DAC; weekly-scale for DAC literature
Where to Inject Abdomen or thigh
Injection Timing Evening is commonly discussed for non-DAC pulses
Effects Timeline IGF-1 changes over weeks in papers
Storage Lyophilized refrigerate; reconstituted 2–8°C
Cycle Length 8–12 weeks
Break Between 4 weeks

Molecular Information

Weight: ~3367 g/mol (peptide core; DAC adduct higher)
Length: 29 amino acids (GHRH 1–29 analogue)
Type: GHRH analogue (DAC or non-DAC)
Formula: —

Amino Acid Sequence

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg + Lys(Mal)-DAC conjugate

Research directions

GH axis Pharmacology

Sustained IGF-1 in DAC papers

Pharmacokinetics

Peak hours (non-DAC) / days (DAC literature)

Half-life ~30 min analogue vs days with DAC

Cleared hours vs many days

Two very different kinetic families share this name.

Literature

Teichman et al., CJC-1295 — 2006 · Clinical PK. DAC analogue prolonged GH/IGF-1.